BIZENGRI® is bi-specific antibody that is indicated for patients with non-small cell lung cancer (NSCLC) or pancreatic adenocarcinoma who harbor an NRG1 gene fusion. FDA granted accelerated approval to BIZENGRI in late 2024. Further development is ongoing and the next indication is expected to launch in 2026. The BIZENGRI® Executive Director, Marketing, will drive commercial growth and market leadership of this precision medicine in its FDA approved indications and future indications. This role combines strategic vision with execution - driving brand strategy, uptake, and being a steward of the commercial culture. This position will partner closely with Sales, Market Access, Medical Affairs, Development, Supply Chain, Operations, and corporate leadership to build brand equity, deepen stakeholder engagement, and ensure sustainable revenue growth in a specialized therapeutic market. The Executive Director, Marketing, will serve as the senior marketer for the product.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Executive
Number of Employees
101-250 employees